top of page
The Sound of Evolution
Empagliflozin
Mechanism of action:
Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Under normal conditions, the kidneys reabsorb almost all filtered glucose. About 90% of this glucose is reabsorbed through SGLT2 in the proximal tubule epithelial cells, while the remaining 10% is reabsorbed through SGLT1. Empagliflozin inhibits SGLT2, preventing glucose reabsorption and increasing urinary glucose excretion.
Reference(s):
1. Scheen AJ et al. (2015). Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet.
2. Gangadharan Komala M et al. (2014). Empagliflozin for the treatment of type 2 diabetes. Expert Rev Clin Pharmacol.
bottom of page